secwatch.observer — SEC 8-K summary
======================================

Issuer:     Envoy Medical, Inc. (COCH)
CIK:        0001840877
Form:       8-K
Filed at:   2026-08-10T20:01:14+00:00
Accession:  0001213900-26-087221
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Envoy Medical posts Q2 loss, submits first FDA PMA module for Acclaim implant
-----------------------------------------------------------------------------

- Q2 2026 net loss of $7.27M ($0.07/share) vs $6.94M ($0.32/share) in Q2 2025; revenue only $51K.
- Submitted first of four modular PMA modules to FDA for Acclaim cochlear implant; final module targeted Q2 2027.
- 12-month Stage 1 data: mean CNC word score 53.2% vs 15.2% baseline (38.0 pp gain), up from 24.0 pp at 6 months.
- R&D spending rose to $3.13M from $2.49M on clinical trial and PMA work; cash ~$19.7M at June 30.
- Terminated $15M ATM equity facility; 4 patents granted in Australia and Europe.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840877/000121390026087221/0001213900-26-087221-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840877/000121390026087221/ea0301372-8k_envoy.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-087221

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer